DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to anchor the treatment of non-small-cell lung cancer (NSCLC), while rapid advances in biomarker-driven strategies are accelerating patient segmentation and…
Bladder Cancer and Upper Tract Urothelial Carcinoma | Disease Landscape and Forecast | G7 | 2025
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…
